JP2021523913A5 - - Google Patents
Info
- Publication number
- JP2021523913A5 JP2021523913A5 JP2020564167A JP2020564167A JP2021523913A5 JP 2021523913 A5 JP2021523913 A5 JP 2021523913A5 JP 2020564167 A JP2020564167 A JP 2020564167A JP 2020564167 A JP2020564167 A JP 2020564167A JP 2021523913 A5 JP2021523913 A5 JP 2021523913A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- seq
- heavy chain
- light chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023183225A JP7680514B2 (ja) | 2018-05-16 | 2023-10-25 | Ｎｋｇ２ｄ、ｃｄ１６、及び線維芽細胞活性化タンパク質と結合するタンパク質 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862672299P | 2018-05-16 | 2018-05-16 | |
| US62/672,299 | 2018-05-16 | ||
| PCT/US2019/032582 WO2019222449A1 (en) | 2018-05-16 | 2019-05-16 | Protein binding nkg2d, cd16 and a fibroblast activation protein |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023183225A Division JP7680514B2 (ja) | 2018-05-16 | 2023-10-25 | Ｎｋｇ２ｄ、ｃｄ１６、及び線維芽細胞活性化タンパク質と結合するタンパク質 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021523913A JP2021523913A (ja) | 2021-09-09 |
| JP2021523913A5 true JP2021523913A5 (enExample) | 2022-05-20 |
| JP7494129B2 JP7494129B2 (ja) | 2024-06-03 |
Family
ID=68540990
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020564167A Active JP7494129B2 (ja) | 2018-05-16 | 2019-05-16 | Ｎｋｇ２ｄ、ｃｄ１６、及び線維芽細胞活性化タンパク質と結合するタンパク質 |
| JP2023183225A Active JP7680514B2 (ja) | 2018-05-16 | 2023-10-25 | Ｎｋｇ２ｄ、ｃｄ１６、及び線維芽細胞活性化タンパク質と結合するタンパク質 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023183225A Active JP7680514B2 (ja) | 2018-05-16 | 2023-10-25 | Ｎｋｇ２ｄ、ｃｄ１６、及び線維芽細胞活性化タンパク質と結合するタンパク質 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20210363261A1 (enExample) |
| EP (1) | EP3793605A4 (enExample) |
| JP (2) | JP7494129B2 (enExample) |
| KR (1) | KR20210010508A (enExample) |
| CN (1) | CN112423788A (enExample) |
| AU (2) | AU2019271263A1 (enExample) |
| BR (1) | BR112020023299A2 (enExample) |
| CA (1) | CA3100234A1 (enExample) |
| MX (1) | MX2020012273A (enExample) |
| SG (1) | SG11202011139YA (enExample) |
| WO (1) | WO2019222449A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018219887B2 (en) | 2017-02-08 | 2024-08-15 | Dragonfly Therapeutics, LLC | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
| CN110944661A (zh) | 2017-02-20 | 2020-03-31 | 蜻蜓疗法股份有限公司 | 结合her2、nkg2d和cd16的蛋白质 |
| CA3237846A1 (en) | 2018-02-08 | 2019-08-15 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting the nkg2d receptor |
| BR112020015994A2 (pt) | 2018-02-08 | 2020-12-15 | Dragonfly Therapeutics, Inc. | Terapia de combinação do câncer que envolve proteínas de ligação multiespecíficas que ativam células natural killer |
| WO2019164930A1 (en) | 2018-02-20 | 2019-08-29 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| EP3833392A4 (en) | 2018-08-08 | 2022-05-18 | Dragonfly Therapeutics, Inc. | MULTISPECIFIC BINDING PROTEINS FOR BINDING CD33, NKG2D AND CD16 AND METHODS OF USE |
| KR102835308B1 (ko) | 2018-08-08 | 2025-07-21 | 드래곤플라이 쎄라퓨틱스, 인크. | Nkg2d, cd16 및 종양 관련 항원에 결합하는 단백질 |
| JP7512394B2 (ja) | 2020-05-06 | 2024-07-08 | ドラゴンフライ セラピューティクス， インコーポレイテッド | Ｎｋｇ２ｄ、ｃｄ１６及びｃｌｅｃ１２ａに結合するタンパク質 |
| EP4284518A4 (en) | 2021-01-27 | 2025-02-19 | Georgetown University | Fibroblast activation protein modulation to alter immune cell migration and tumor infiltration |
| EP4301774A4 (en) | 2021-03-03 | 2025-08-13 | Dragonfly Therapeutics Inc | METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN |
| EP4311557A1 (en) * | 2022-07-26 | 2024-01-31 | Oncomatryx Biopharma, S.L. | Fap-targeted antibody-drug conjugates |
| TW202540200A (zh) | 2023-12-01 | 2025-10-16 | 美商基利科學股份有限公司 | 抗ｆａｐ－ｌｉｇｈｔ融合蛋白及其用途 |
| WO2025244097A1 (ja) * | 2024-05-23 | 2025-11-27 | オプティアム・バイオテクノロジーズ株式会社 | 改良型抗ＦＡＰα－キメラ抗原受容体 |
| CN119265201A (zh) * | 2024-08-23 | 2025-01-07 | 中国人民解放军海军军医大学第一附属医院 | 编码基因、蛋白、表达il-15的nkg2dl-fap双靶点car-nk细胞及其构建方法和用途 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101300272B (zh) * | 2005-10-14 | 2013-09-18 | 依奈特制药公司 | 用于治疗增生性病症的组合物和方法 |
| AU2008337517B2 (en) * | 2007-12-14 | 2014-06-26 | Novo Nordisk A/S | Antibodies against human NKG2D and uses thereof |
| WO2010017103A2 (en) * | 2008-08-04 | 2010-02-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic | Fully human anti-human nkg2d monoclonal antibodies |
| UY32808A (es) * | 2009-07-29 | 2011-02-28 | Abbott Lab | Inmunoglobulinas como dominio variable dual y usos de las mismas |
| JP5764127B2 (ja) * | 2009-08-17 | 2015-08-12 | ロシュ グリクアート アーゲー | 標的化イムノコンジュゲート |
| CA2806021C (en) * | 2010-08-13 | 2019-05-21 | Roche Glycart Ag | Anti-fap antibodies and methods of use |
| HUE033245T2 (hu) * | 2011-12-19 | 2017-11-28 | Synimmune Gmbh | Bispecifikus ellenanyag molekula |
| GB201402006D0 (en) * | 2014-02-06 | 2014-03-26 | Oncomatryx Biopharma S L | Antibody-drug conjugates and immunotoxins |
| CA2973720A1 (en) * | 2015-01-14 | 2016-07-21 | Compass Therapeutics Llc | Multispecific immunomodulatory antigen-binding constructs |
| DK3313876T3 (da) * | 2015-06-23 | 2025-04-22 | Innate Pharma | Multispecifikke antigenbindende proteiner |
| WO2017124002A1 (en) * | 2016-01-13 | 2017-07-20 | Compass Therapeutics Llc | Multispecific immunomodulatory antigen-binding constructs |
| WO2017165464A1 (en) * | 2016-03-21 | 2017-09-28 | Elstar Therapeutics, Inc. | Multispecific and multifunctional molecules and uses thereof |
| JP2018035137A (ja) * | 2016-07-13 | 2018-03-08 | マブイミューン ダイアグノスティックス エイジーＭａｂｉｍｍｕｎｅ Ｄｉａｇｎｏｓｔｉｃｓ Ａｇ | 新規な抗線維芽細胞活性化タンパク質（ｆａｐ）結合薬剤およびその使用 |
| AU2018219887B2 (en) * | 2017-02-08 | 2024-08-15 | Dragonfly Therapeutics, LLC | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
| EP3668893A4 (en) * | 2017-08-16 | 2021-08-04 | Dragonfly Therapeutics, Inc. | PROTEINS BINDING TO NKG2D, CD16 AND EGFR, HLA-E, CCR4, OR PD-L1 |
-
2019
- 2019-05-16 AU AU2019271263A patent/AU2019271263A1/en not_active Abandoned
- 2019-05-16 CA CA3100234A patent/CA3100234A1/en active Pending
- 2019-05-16 CN CN201980047481.2A patent/CN112423788A/zh active Pending
- 2019-05-16 US US17/055,792 patent/US20210363261A1/en not_active Abandoned
- 2019-05-16 KR KR1020207035733A patent/KR20210010508A/ko not_active Ceased
- 2019-05-16 BR BR112020023299-8A patent/BR112020023299A2/pt unknown
- 2019-05-16 MX MX2020012273A patent/MX2020012273A/es unknown
- 2019-05-16 SG SG11202011139YA patent/SG11202011139YA/en unknown
- 2019-05-16 WO PCT/US2019/032582 patent/WO2019222449A1/en not_active Ceased
- 2019-05-16 JP JP2020564167A patent/JP7494129B2/ja active Active
- 2019-05-16 EP EP19803947.1A patent/EP3793605A4/en active Pending
-
2023
- 2023-10-25 JP JP2023183225A patent/JP7680514B2/ja active Active
-
2026
- 2026-02-26 AU AU2026201454A patent/AU2026201454A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021523913A5 (enExample) | ||
| JP2023509448A5 (enExample) | ||
| JP2021534096A5 (enExample) | ||
| JP2025111463A5 (enExample) | ||
| JP2020522474A5 (enExample) | ||
| JP2022061993A5 (enExample) | ||
| JP2021035388A5 (ja) | Ｃａｉｘ、ａｎｏ１、メソテリン、ｔｒｏｐ２またはクローディン−１８．２を標的にする多重特異性結合タンパク質 | |
| JP2021523140A5 (enExample) | ||
| JP2020510653A5 (ja) | Ｃｅａを標的にする多重特異性結合タンパク質 | |
| JP2023123726A5 (enExample) | ||
| JP2020531438A5 (ja) | Ｎｋｇ２ｄ、ｃｄ１６、およびｈｌａ−ｅに結合するタンパク質 | |
| JP2020521448A5 (enExample) | ||
| JP2019536430A5 (enExample) | ||
| JP2022507487A5 (enExample) | ||
| JP2020508997A5 (enExample) | ||
| JP2021522162A5 (enExample) | ||
| JP2021533159A5 (enExample) | ||
| JP2013527761A5 (enExample) | ||
| JP2023516004A5 (enExample) | ||
| JP2020514277A5 (enExample) | ||
| JP2021522347A5 (enExample) | ||
| RU2019129511A (ru) | Белки, связывающие gd2, nkg2d и cd16 | |
| JP2024504390A5 (enExample) | ||
| JP2024016024A5 (enExample) | ||
| JP2024532489A5 (enExample) |